首页 > 最新文献

Future cardiology最新文献

英文 中文
Cost-effectiveness of continuous real-time intracardiac recurrent event detection and alerting in high-risk acute coronary syndrome patients.
IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-01 Epub Date: 2025-01-31 DOI: 10.1080/14796678.2025.2457831
Gillian D Sanders Schmidler, M Sasha John, Jeffrey D Voigt, Mitchell W Krucoff

Background: ALERTS was a pivotal randomized clinical trial (RCT) evaluating an intracardiac monitor with real-time alerting in high-risk acute coronary syndrome patients. The cost-effectiveness however is unknown.

Method: A decision model estimated health effects and costs of implanting a Guardian device in a target patient population, compared to current standard-of-care (SOC). Health and economic outcomes were modeled using ALERTS trial results and relevant literature.

Results: Base-case analysis indicated an incremental lifetime cost of $21,988 with Guardian as compared to SOC (increase of 0.18 life years or 0.37 quality-adjusted life years (QALY)). The incremental cost-effectiveness ratio (ICER) was $121,056/LY or $58,668/QALY.

Conclusion: Real-time intracardiac monitoring with patient alerting was cost-effective using conventional thresholds in acute coronary syndrome (ACS) patients at high-risk for recurrent events.

{"title":"Cost-effectiveness of continuous real-time intracardiac recurrent event detection and alerting in high-risk acute coronary syndrome patients.","authors":"Gillian D Sanders Schmidler, M Sasha John, Jeffrey D Voigt, Mitchell W Krucoff","doi":"10.1080/14796678.2025.2457831","DOIUrl":"10.1080/14796678.2025.2457831","url":null,"abstract":"<p><strong>Background: </strong>ALERTS was a pivotal randomized clinical trial (RCT) evaluating an intracardiac monitor with real-time alerting in high-risk acute coronary syndrome patients. The cost-effectiveness however is unknown.</p><p><strong>Method: </strong>A decision model estimated health effects and costs of implanting a Guardian device in a target patient population, compared to current standard-of-care (SOC). Health and economic outcomes were modeled using ALERTS trial results and relevant literature.</p><p><strong>Results: </strong>Base-case analysis indicated an incremental lifetime cost of $21,988 with Guardian as compared to SOC (increase of 0.18 life years or 0.37 quality-adjusted life years (QALY)). The incremental cost-effectiveness ratio (ICER) was $121,056/LY or $58,668/QALY.</p><p><strong>Conclusion: </strong>Real-time intracardiac monitoring with patient alerting was cost-effective using conventional thresholds in acute coronary syndrome (ACS) patients at high-risk for recurrent events.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"83-93"},"PeriodicalIF":1.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multivalvular vs single-valve infective endocarditis: a systematic review and meta-analysis.
IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-01 Epub Date: 2025-01-30 DOI: 10.1080/14796678.2025.2457898
Ioannis Kyriakoulis, Andreas Tzoumas, Konstantinos G Kyriakoulis, Ioannis Kardoutsos, Athina Ntoumaziou, Sanjana Nagraj, Damianos G Kokkinidis, Leonidas Palaiodimos

Background: Infective endocarditis is characterized by the colonization of heart valves by virulent microorganisms. It commonly manifests as involvement of a single heart valve -single-valve infective endocarditis (SIE), while in some patients, two or more heart valves are concomitantly infected -multivalvular infective endocarditis (MIE). The risk of complications and prognosis of MIE as opposed to SIE are unknown.

Methods: We performed a systematic search in MEDLINE and Scopus for studies of patients with MIE and SIE. The outcomes of interest included mortality, heart failure, systemic embolic events, and need for surgery.

Results: Οf 1,124 identified studies, eleven met the inclusion criteria. MIE was reported in 20.4% of the total patients. Compared to SIE, MIE was associated with increased risk of short-term mortality (RR: 1.29, 95% CI: 1.19-1.39), one-year mortality (RR: 1.20, 95% CI: 1.08-1.34), heart failure (RR: 1.31, 95% CI: 1.12-1.54), systemic embolic events (RR: 1.12, 95% CI: 1.02-1.22), and need for subsequent surgical management (RR: 1.22, 95% CI: 1.05-1.41).

Conclusions: Patients with MIE have a higher likelihood of poor prognosis compared to patients with SIE. A high clinical suspicion of this condition and timely diagnosis and management are imperative while managing patients with infective endocarditis.

Protocol registration: PROSPERO CRD42023486674.

{"title":"Multivalvular vs single-valve infective endocarditis: a systematic review and meta-analysis.","authors":"Ioannis Kyriakoulis, Andreas Tzoumas, Konstantinos G Kyriakoulis, Ioannis Kardoutsos, Athina Ntoumaziou, Sanjana Nagraj, Damianos G Kokkinidis, Leonidas Palaiodimos","doi":"10.1080/14796678.2025.2457898","DOIUrl":"10.1080/14796678.2025.2457898","url":null,"abstract":"<p><strong>Background: </strong>Infective endocarditis is characterized by the colonization of heart valves by virulent microorganisms. It commonly manifests as involvement of a single heart valve -single-valve infective endocarditis (SIE), while in some patients, two or more heart valves are concomitantly infected -multivalvular infective endocarditis (MIE). The risk of complications and prognosis of MIE as opposed to SIE are unknown.</p><p><strong>Methods: </strong>We performed a systematic search in MEDLINE and Scopus for studies of patients with MIE and SIE. The outcomes of interest included mortality, heart failure, systemic embolic events, and need for surgery.</p><p><strong>Results: </strong>Οf 1,124 identified studies, eleven met the inclusion criteria. MIE was reported in 20.4% of the total patients. Compared to SIE, MIE was associated with increased risk of short-term mortality (RR: 1.29, 95% CI: 1.19-1.39), one-year mortality (RR: 1.20, 95% CI: 1.08-1.34), heart failure (RR: 1.31, 95% CI: 1.12-1.54), systemic embolic events (RR: 1.12, 95% CI: 1.02-1.22), and need for subsequent surgical management (RR: 1.22, 95% CI: 1.05-1.41).</p><p><strong>Conclusions: </strong>Patients with MIE have a higher likelihood of poor prognosis compared to patients with SIE. A high clinical suspicion of this condition and timely diagnosis and management are imperative while managing patients with infective endocarditis.</p><p><strong>Protocol registration: </strong>PROSPERO CRD42023486674.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"113-121"},"PeriodicalIF":1.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current approach to atherosclerotic cardiovascular disease risk prediction. 目前预测动脉粥样硬化性心血管疾病风险的方法。
IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-01 Epub Date: 2024-11-24 DOI: 10.1080/14796678.2024.2433349
Wahab J Khan, Dinesh K Kalra
{"title":"Current approach to atherosclerotic cardiovascular disease risk prediction.","authors":"Wahab J Khan, Dinesh K Kalra","doi":"10.1080/14796678.2024.2433349","DOIUrl":"10.1080/14796678.2024.2433349","url":null,"abstract":"","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"67-69"},"PeriodicalIF":1.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current and future role of PCSK9 inhibitors in ASCVD prevention. PCSK9抑制剂在ASCVD预防中的当前和未来作用
IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-01 Epub Date: 2025-01-05 DOI: 10.1080/14796678.2025.2450189
Antonio Greco, Davide Capodanno
{"title":"Current and future role of PCSK9 inhibitors in ASCVD prevention.","authors":"Antonio Greco, Davide Capodanno","doi":"10.1080/14796678.2025.2450189","DOIUrl":"10.1080/14796678.2025.2450189","url":null,"abstract":"","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"71-73"},"PeriodicalIF":1.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Congenital cardiac surgical simulation: bridging global workforce gaps and optimizing outcomes.
IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-01 Epub Date: 2025-01-25 DOI: 10.1080/14796678.2025.2458402
Mimi X Deng, Dominique Vervoort, Israel Valverde, Shi-Joon Yoo, Brandon Peel, Rachel D Vanderlaan, David J Barron, Osami Honjo

Reaching competency in congenital heart surgery (CHS) requires lengthy and rigorous training. Due to patient safety, time limitations, and procedural complexity, the intraoperative setting is not ideal for technical practice. Surgical simulation using synthetic, biological, or virtual models is an increasingly valuable educational tool for technical training and assessment. In particular, three-dimensional (3D) models are especially favorable in CHS education for its high-fidelity demonstration of congenital heart defects. In countries where there is a deficit of local cardiac surgical expertise, simple and inexpensive innovation, such as expanding hands-on technical training programs involving 3D-models and hybrid teaching, may partially address the lack of CHS training opportunities and the consequent unmet need for surgical management of pediatric heart disease.

{"title":"Congenital cardiac surgical simulation: bridging global workforce gaps and optimizing outcomes.","authors":"Mimi X Deng, Dominique Vervoort, Israel Valverde, Shi-Joon Yoo, Brandon Peel, Rachel D Vanderlaan, David J Barron, Osami Honjo","doi":"10.1080/14796678.2025.2458402","DOIUrl":"10.1080/14796678.2025.2458402","url":null,"abstract":"<p><p>Reaching competency in congenital heart surgery (CHS) requires lengthy and rigorous training. Due to patient safety, time limitations, and procedural complexity, the intraoperative setting is not ideal for technical practice. Surgical simulation using synthetic, biological, or virtual models is an increasingly valuable educational tool for technical training and assessment. In particular, three-dimensional (3D) models are especially favorable in CHS education for its high-fidelity demonstration of congenital heart defects. In countries where there is a deficit of local cardiac surgical expertise, simple and inexpensive innovation, such as expanding hands-on technical training programs involving 3D-models and hybrid teaching, may partially address the lack of CHS training opportunities and the consequent unmet need for surgical management of pediatric heart disease.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"123-129"},"PeriodicalIF":1.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812351/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elevated Lp(a) and its association with cardiac fibrosis in group II pulmonary hypertension patients.
IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-01 Epub Date: 2025-02-02 DOI: 10.1080/14796678.2025.2460909
Arif Albulushi, Shabib Al-Asmi, Moosa Al-Abri, Hatem Al-Farhan

Background: Group II Pulmonary Hypertension (PH) secondary to Heart Failure with preserved Ejection Fraction (HFpEF) is associated with significant morbidity and mortality. Lipoprotein(a) [Lp(a)] is a novel biomarker implicated in cardiovascular pathology, yet its role in myocardial fibrosis within this population remains underexplored. This study investigates the association between elevated Lp(a) levels and cardiac fibrosis to improve understanding of its prognostic and diagnostic utility.

Methods: This retrospective cohort study included 100 patients with Group II PH secondary to HFpEF. Serum Lp(a) levels were quantified using enzymatic assays, and myocardial fibrosis was assessed using Cardiac Magnetic Resonance Imaging (CMR) techniques, including T1 mapping and late gadolinium enhancement (LGE). Statistical models adjusted for confounding factors.

Results: Elevated Lp(a) levels were significantly associated with increased myocardial extracellular volume (31% vs. 27%, p < 0.01), prolonged native T1 times, and increased odds of myocardial scar formation. Structural cardiac changes correlated with Lp(a) concentrations.

Conclusion: Elevated Lp(a) is a key marker of myocardial fibrosis and structural remodeling in Group II PH secondary to HFpEF. Routine Lp(a) measurement may enhance risk stratification and inform therapeutic strategies.

{"title":"Elevated Lp(a) and its association with cardiac fibrosis in group II pulmonary hypertension patients.","authors":"Arif Albulushi, Shabib Al-Asmi, Moosa Al-Abri, Hatem Al-Farhan","doi":"10.1080/14796678.2025.2460909","DOIUrl":"10.1080/14796678.2025.2460909","url":null,"abstract":"<p><strong>Background: </strong>Group II Pulmonary Hypertension (PH) secondary to Heart Failure with preserved Ejection Fraction (HFpEF) is associated with significant morbidity and mortality. Lipoprotein(a) [Lp(a)] is a novel biomarker implicated in cardiovascular pathology, yet its role in myocardial fibrosis within this population remains underexplored. This study investigates the association between elevated Lp(a) levels and cardiac fibrosis to improve understanding of its prognostic and diagnostic utility.</p><p><strong>Methods: </strong>This retrospective cohort study included 100 patients with Group II PH secondary to HFpEF. Serum Lp(a) levels were quantified using enzymatic assays, and myocardial fibrosis was assessed using Cardiac Magnetic Resonance Imaging (CMR) techniques, including T1 mapping and late gadolinium enhancement (LGE). Statistical models adjusted for confounding factors.</p><p><strong>Results: </strong>Elevated Lp(a) levels were significantly associated with increased myocardial extracellular volume (31% vs. 27%, <i>p</i> < 0.01), prolonged native T1 times, and increased odds of myocardial scar formation. Structural cardiac changes correlated with Lp(a) concentrations.</p><p><strong>Conclusion: </strong>Elevated Lp(a) is a key marker of myocardial fibrosis and structural remodeling in Group II PH secondary to HFpEF. Routine Lp(a) measurement may enhance risk stratification and inform therapeutic strategies.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"95-102"},"PeriodicalIF":1.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Air pollution and coronary atherosclerosis. 空气污染与冠状动脉硬化
IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-01-01 Epub Date: 2025-01-09 DOI: 10.1080/14796678.2025.2451545
Andrea Caffè, Vincenzo Scarica, Francesco Maria Animati, Matteo Manzato, Alice Bonanni, Rocco Antonio Montone

The recently introduced concept of 'exposome' emphasizes the impact of non-traditional threats onto cardiovascular health. Among these, air pollutants - particularly fine particulate matter < 2.5 μm (PM2.5) - have emerged as significant environmental risk factors for cardiovascular disease and mortality. PM2.5 exposure has been shown to induce endothelial dysfunction, chronic low-grade inflammation, and cardiometabolic impairment, contributing to the development and destabilization of atherosclerotic plaques. Both short- and long-term exposure to air pollution considerably increase the incidence of ischemic heart disease (IHD)-related events, with clinical evidence linking pollution to higher mortality and adverse prognosis, especially in vulnerable populations. In this review, we explore the mechanistic pathways through which air pollutants exacerbate atherosclerotic cardiovascular disease (ASCVD) and discuss their clinical impact.Furthermore, special attention will be directed to the outcomes and prognosis of patients with pollution-aggravated coronary atherosclerosis, as well as the potential role of targeted public health interventions.

最近提出的“暴露”概念强调非传统威胁对心血管健康的影响。其中包括空气污染物,尤其是细颗粒物
{"title":"Air pollution and coronary atherosclerosis.","authors":"Andrea Caffè, Vincenzo Scarica, Francesco Maria Animati, Matteo Manzato, Alice Bonanni, Rocco Antonio Montone","doi":"10.1080/14796678.2025.2451545","DOIUrl":"10.1080/14796678.2025.2451545","url":null,"abstract":"<p><p>The recently introduced concept of 'exposome' emphasizes the impact of non-traditional threats onto cardiovascular health. Among these, air pollutants - particularly fine particulate matter < 2.5 μm (PM2.5) - have emerged as significant environmental risk factors for cardiovascular disease and mortality. PM2.5 exposure has been shown to induce endothelial dysfunction, chronic low-grade inflammation, and cardiometabolic impairment, contributing to the development and destabilization of atherosclerotic plaques. Both short- and long-term exposure to air pollution considerably increase the incidence of ischemic heart disease (IHD)-related events, with clinical evidence linking pollution to higher mortality and adverse prognosis, especially in vulnerable populations. In this review, we explore the mechanistic pathways through which air pollutants exacerbate atherosclerotic cardiovascular disease (ASCVD) and discuss their clinical impact.Furthermore, special attention will be directed to the outcomes and prognosis of patients with pollution-aggravated coronary atherosclerosis, as well as the potential role of targeted public health interventions.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"53-66"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812424/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bodyweight affects mortality in an L-shape pattern in patients undergoing coronary bypass grafting. 体重对冠状动脉旁路移植术患者死亡率的影响呈l型。
IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-01-01 Epub Date: 2025-01-05 DOI: 10.1080/14796678.2024.2440247
Bardia Lajevardi, Armin Talle, Mehrtash Hashemzadeh, Mohammad Reza Movahed

Background: The role of body composition as a risk factor for adverse outcomesduring coronary artery bypass surgery (CABG) has been controversial. The goal of this study was to evaluate the effect of body weight on mortality in patients undergoing CABG.

Method: Using a large NIS database and ICD-10 coding for different bodyweight categories, we evaluated the effect of cachexia, overweight, obesity, and morbid obesity on in-hospital mortality after CABG.  We evaluated the available database containing ICD10 coding from 2016- 2020.

Results: We found that cachexia was the strongest independent predictor of in-hospital mortality whereas obesity had a protective effect. Over the 4-year sample size, patients with cachexia had nearly a 4-fold increase in mortality compared to patients with normal weight despite adjusting for age and comorbidities (4.06 CI 2.7-6.0, p < 0.001). Patients with overweight and Obesity had the lowest mortality (OR = 0.44 CI 0.29-0.66, OR = 0.58 CI 0.52-0.63, p, 001). However, the mortality benefit disappeared in patients with morbid obesity (OR 0.9, CI 0.84-1.03, p = 0.15) with a trend of higher mortality in patients with morbid obesity after multivariate adjustment.

Conclusion: Cachexia is a powerful predictor for in-hospital mortality in patients undergoing CABG. Overweight and obesity have protective effect which disappears with morbid obesity.

背景:体成分作为冠状动脉搭桥手术(CABG)不良结果的危险因素的作用一直存在争议。本研究的目的是评估体重对冠脉搭桥患者死亡率的影响。方法:利用大型NIS数据库和不同体重类别的ICD-10编码,我们评估了病毒质、超重、肥胖和病态肥胖对冠状动脉绕道术后住院死亡率的影响。我们评估了包含2016- 2020年ICD10编码的可用数据库。结果:我们发现恶病质是院内死亡率最强的独立预测因子,而肥胖具有保护作用。在4年的样本量中,尽管调整了年龄和合并症,但恶病质患者的死亡率比正常体重患者增加了近4倍(4.06 CI 2.7-6.0, p p = 0.15),并且在多因素调整后,病态肥胖患者的死亡率有更高的趋势。结论:恶病质是冠脉搭桥患者住院死亡率的重要预测因子。超重和肥胖具有保护作用,但随着病态肥胖而消失。
{"title":"Bodyweight affects mortality in an L-shape pattern in patients undergoing coronary bypass grafting.","authors":"Bardia Lajevardi, Armin Talle, Mehrtash Hashemzadeh, Mohammad Reza Movahed","doi":"10.1080/14796678.2024.2440247","DOIUrl":"10.1080/14796678.2024.2440247","url":null,"abstract":"<p><strong>Background: </strong>The role of body composition as a risk factor for adverse outcomesduring coronary artery bypass surgery (CABG) has been controversial. The goal of this study was to evaluate the effect of body weight on mortality in patients undergoing CABG.</p><p><strong>Method: </strong>Using a large NIS database and ICD-10 coding for different bodyweight categories, we evaluated the effect of cachexia, overweight, obesity, and morbid obesity on in-hospital mortality after CABG.  We evaluated the available database containing ICD10 coding from 2016- 2020.</p><p><strong>Results: </strong>We found that cachexia was the strongest independent predictor of in-hospital mortality whereas obesity had a protective effect. Over the 4-year sample size, patients with cachexia had nearly a 4-fold increase in mortality compared to patients with normal weight despite adjusting for age and comorbidities (4.06 CI 2.7-6.0, <i>p</i> < 0.001). Patients with overweight and Obesity had the lowest mortality (OR = 0.44 CI 0.29-0.66, OR = 0.58 CI 0.52-0.63, p, 001). However, the mortality benefit disappeared in patients with morbid obesity (OR 0.9, CI 0.84-1.03, <i>p</i> = 0.15) with a trend of higher mortality in patients with morbid obesity after multivariate adjustment.</p><p><strong>Conclusion: </strong>Cachexia is a powerful predictor for in-hospital mortality in patients undergoing CABG. Overweight and obesity have protective effect which disappears with morbid obesity.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"9-14"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812328/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GLP-1 receptor agonists and SGLT2 inhibitors: new anti-aging tools? GLP-1 受体激动剂和 SGLT2 抑制剂:新的抗衰老工具?
IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-01-01 Epub Date: 2024-11-26 DOI: 10.1080/14796678.2024.2433381
Gaetano Santulli, Pasquale Mone, Fahimeh Varzideh
{"title":"GLP-1 receptor agonists and SGLT2 inhibitors: new anti-aging tools?","authors":"Gaetano Santulli, Pasquale Mone, Fahimeh Varzideh","doi":"10.1080/14796678.2024.2433381","DOIUrl":"10.1080/14796678.2024.2433381","url":null,"abstract":"","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"5-8"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142727627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The shortcomings of the Medina compared to the Movahed coronary bifurcation classification. 将麦地那冠状动脉分岔的缺点与Movahed冠状动脉分岔进行比较。
IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-01-01 Epub Date: 2024-12-23 DOI: 10.1080/14796678.2024.2444156
Mohammad Reza Movahed

The Medina classification separates true bifurcation lesions into three unnecessary groups: 1.1.1, 1.0.1, and 0.1.1. Non-true bifurcation lesions are divided into three unnecessary subgroups called 0.0.1, 0.1.0, and 1.0.0. Furthermore, the Medina classification does not describe any other important features of a given bifurcation lesion, making it useless when comparing complex bifurcation lesions. This has led to confusion in clinical settings and stagnation of bifurcation research. The Movahed bifurcation classification has overcome those problems by summarizing all true bifurcation lesions into one simple relevant category called B2 (B for bifurcation, 2 meaning both main and side branches at bifurcation site have significant lesions) and non-true bifurcation lesions into two simple categories called B1m (B for bifurcation, 1 m meaning only the main branch has significant lesion) and B1S lesions (B for bifurcation and 1 s meaning only the side branch has significant lesion). Moreover, at the same time, additional unlimited suffixes can be added if needed to describe a given bifurcation lesion, making this bifurcation also very comprehensive. In this perspective, the shortcomings of the Medina classification compared to the Movahed classification are discussed in detail.

Medina分类将真正的分叉病变分为三个不必要的组:1.1.1,1.0.1和0.1.1。非真分叉病变分为三个不必要的亚组,分别为0.0.1、0.1.0和1.0.0。此外,Medina分类不描述任何其他重要特征的一个给定的分岔病变,使其无用的比较复杂的分岔病变。这导致了临床环境的混乱和分岔研究的停滞。Movahed分岔分类法克服了这些问题,它将所有真分岔病变归纳为一个简单的相关类别,称为B2 (B表示分岔,2表示分岔部位的主分支和侧分支都有明显病变),将非真分岔病变归纳为两个简单类别,称为B1m (B表示分岔,1 m表示只有主干有明显病变)和B1S病变(B表示分叉,1s表示只有侧主干有明显病变)。同时,如果需要描述一个给定的分岔病灶,还可以添加无限的后缀,使得这个分岔也非常全面。从这个角度,详细讨论了Medina分类与Movahed分类相比的缺点。
{"title":"The shortcomings of the Medina compared to the Movahed coronary bifurcation classification.","authors":"Mohammad Reza Movahed","doi":"10.1080/14796678.2024.2444156","DOIUrl":"10.1080/14796678.2024.2444156","url":null,"abstract":"<p><p>The Medina classification separates true bifurcation lesions into three unnecessary groups: 1.1.1, 1.0.1, and 0.1.1. Non-true bifurcation lesions are divided into three unnecessary subgroups called 0.0.1, 0.1.0, and 1.0.0. Furthermore, the Medina classification does not describe any other important features of a given bifurcation lesion, making it useless when comparing complex bifurcation lesions. This has led to confusion in clinical settings and stagnation of bifurcation research. The Movahed bifurcation classification has overcome those problems by summarizing all true bifurcation lesions into one simple relevant category called B2 (B for bifurcation, 2 meaning both main and side branches at bifurcation site have significant lesions) and non-true bifurcation lesions into two simple categories called B1m (B for bifurcation, 1 m meaning only the main branch has significant lesion) and B1S lesions (B for bifurcation and 1 s meaning only the side branch has significant lesion). Moreover, at the same time, additional unlimited suffixes can be added if needed to describe a given bifurcation lesion, making this bifurcation also very comprehensive. In this perspective, the shortcomings of the Medina classification compared to the Movahed classification are discussed in detail.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"31-37"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Future cardiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1